Laboratory approaches to the diagnosis of hepatitis C virus infection

Minerva Gastroenterologica e Dietologica

Volumn 50, Issue 1, 2004, Pages 9-20

  Jerome, K R ^a,b   Gretch, D R ^a,c  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hepatitis C, diagnosis; Hepatitis C, immunology; Hepatitis C, therapy

Indexed keywords

HEPATITIS C ANTIBODY; NEW DRUG;

ANTIBODY DETECTION; DIAGNOSTIC PROCEDURE; EPIDEMIC; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LABORATORY TEST; MEDICAL DECISION MAKING; PATIENT MONITORING; PROGNOSIS; REVIEW; SCREENING; SERODIAGNOSIS; VIRUS REPLICATION;

GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 2442510939     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. MacCallum FO. Early studies of viral hepatitis. Br Med Bull 1972;28:105-8.
2. Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemia sera. JAMA 1965;191:541-6.
3. Lander JJ, Alter HJ, Purcell RH. Frequency of antibody to hepatitis-associated antigen as measured by a new radioimmunoassay technique. J Immunol 1971;106: 1166-71.
4. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975;292:767-70.
5. Koretz RL, Klahs DR, Ritman S, Damus KH, Gitnick GL. Post-transfusion hepatitis in recipients of blood screened by newer assays. Lancet 1973;2:694-6.
6. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
7. Weiner AJ, Truett MA, Rosenblatt J, Han J, Quan S, Polito AJ et al. HCV testing in low-risk population. Lancet 1990;336:695.
8. Kato N, Yokosuka O, Omata M, Hosoda K, Ohto M. Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest 1990;86:1764-7.
9. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36:S30-4.
10. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
11. Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol 2003;36:47-53.
12. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62S-5.
13. Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. J Infect Dis 2000;182:1588-94.
14. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655-61.
15. Mattsson L, Aberg B, Weiland O, Sellman M, Davilen J. Non-A, non-B hepatitis after open-heart surgery in Stockholm: declining incidence after introduction of restrictions for blood donations due to the human immunodeficiency virus. Scand J Infect Dis 1988; 20:371-6.
16. Dore GJ, Kaldor JM, McCaughan GW. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ 1997;315:333-7.
17. Donahue JG, Munoz A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-73.
18. Pereira BJ, Milford EL, Kirkman RL, Quan S, Sayre KR, Johnson PJ et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 1992; 327:910-5.
19. Conrad EU, Gretch DR, Obermeyer KR, Moogk MS, Sayers M, Wilson JJ et al. Transmission of the hepatitis-C virus by tissue transplantation. J Bone Joint Surg Am 1995;77:214-24.
20. Fabrizi F, Martin P. Hepatitis C virus infection in dialysis: an emerging clinical reality. Int J Artif Organs 2001; 24:123-30.
21. Lanphear BP, Linnemann CC Jr, Cannon CG, DeRonde MM, Pendy L, Kerley LM. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol 1994;15:745-50.
22. Mitsui T, Iwano K, Masuko K, Yamazaki C, Okamoto H, Tsuda F et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992; 16:1109-14.
23. Sartori M, La Terra G, Aglietta M, Manzin A, Navino C, Verzetti G. Transmission of hepatitis C via blood splash into conjunctiva. Scand J Infect Dis 1993;25:270-1.
24. Ippolito G, Puro V, Petrosillo N, De Carli G, Micheloni G, Magliano E. Simultaneous infection with HIV and hepatitis C virus following occupational conjunctival blood exposure. JAMA 1998;280:28.
25. Alter MJ, Coleman PJ, Alexander WJ, Kramer E, Miller JK, Mandel E et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989;262:1201-5.
26. Zylberberg H, Thiers V, Lagorce D, Squadrito G, Leone F, Berthelot P et al. Epidemiological and virological analysis of couples infected with hepatitis C virus. Gut 1999;45:112-6.
27. Piazza M, Sagliocca L, Tosone G, Guadagnino V, Stazi MA, Orlando R et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 1997;157:1537-44.
28. Thomas DL, Zenilman JM, Alter HJ, Shih JW, Galai N, Carella AV et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore: an analysis of 309 sex partnerships. J Infect Dis 1995;171:768-75.
29. Tajiri H, Miyoshi Y, Funada S, Etani Y, Abe J, Onodera T et al. Prospective study of mother-to-infant transmission of hepatitis C virus. Pediatr Infect Dis J 2001; 20:10-4.
30. Gibb DM, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000;356:904-7.
31. Thaler MM, Park CK, Landers DV, Wara DW, Houghton M, Veereman-Wauters G et al. Vertical transmission of hepatitis C virus. Lancet 1991;338:17-8.
32. Lin HH, Kao JH, Hsu HY, Ni YH, Yeh SH, Hwang LH et al. Possible role of high-titer maternal viremia in perinatal transmission of hepatitis C virus. J Infect Dis 1994;169:638-41.
33. Willson RA. Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol 1997;92:3-17.
34. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
35. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997;26:83S-8.
36. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
37. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
38. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
39. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-9.
40. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 1991;88: 2451-5.
41. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74(Pt 11):2391-9.
42. Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 2003;7:45-66.
43. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001;15:883-95.
44. Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991;180: 842-8.
45. Davis GL, Lau JY, Urdea MS, Neuwald PD, Wilber JC, Lindsay K et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994;19:1337-41.
46. Polyak SJ, McArdle S, Liu SL, Sullivan DG, Chung M, Hofgartner WT et al. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 1998; 72:4288-96.
47. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001;8: 87-95.
48. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002;123:2082-99.
49. Gretch DR. Diagnostic tests for hepatitis C. Hepatology 1997;26:43S-7.
50. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003;52:1-13, 15; quiz CE1-4.
51. Ferrer F, Candela MJ, Garcia C, Martinez L, Rivera J, Vicente V. A comparative study of two third-generation anti-hepatitis C virus ELISAs. Haematologica 1997; 82:690-1.
52. Tobler LH, Tegtmeier G, Stramer SL, Quan S, Dockter J, Giachetti C et al. Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays: justification and rational implementation. Transfusion 2000;40:15-24.
53. Fabrizi F, Martin P, Dixit V, Quan S, Brezina M, Kaufman E et al. Automated RIBA HCV strip immunoblot assay: a novel tool for the diagnosis of hepatitis C virus infection in hemodialysis patients. Am J Nephrol 2001; 21:104-11.
54. Courouce AM, Le Marrec N, Girault A, Ducamp S, Simon N. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second- and third-generation anti-HCV assays. Transfusion 1994;34:790-5.
55. Damen M, Zaaijer HL, Cuypers HT, Vrielink H, van der Poel CL, Reesink HW et al. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Transfusion 1995;35:745-9.
56. Busch MP, Wilber JC, Johnson P, Tobler L, Evans CS. Impact of specimen handling and storage on detection of hepatitis C virus RNA. Transfusion 1992;32: 420-5.
57. Morishima C, Gretch DR. Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy. Clin Liver Dis 1999;3:717-40.
58. Damen M, Cuypers HT, Zaaijer HL, Reesink HW, Schaasberg WP, Gerlich WH et al. International collaborative study on the second EUROHEP HCV-RNA reference panel. J Virol Methods 1996;58:175-85.
59. Martinot-Peignoux M, Le Breton V, Fritsch S, Le Guludec G, Labouret N, Keller F et al. Assessment of viral loads in patients with chronic hepatitis C with AMPLICOR HCV MONITOR version 1.0, COBAS HCV MONITOR version 2.0, and QUANTIPLEX HCV RNA version 2.0 assays. J Clin Microbiol 2000;38:2722-5.
60. Ross RS, Viazov SO, Hoffmann S, Roggendorf M. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA. J Clin Lab Anal 2001; 15:308-13.
61. Comanor L, Anderson F, Ghany M, Perrillo R, Heathcote EJ, Sherlock C et al. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol 2001;96:2968-72.
62. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000;32: 818-23.
63. Morishima C, Chung M, Ng KW, Brambilla DJ, Gretch DR. Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. J Clin Microbiol 2004;42:421-5.
64. Castro FJ, Sauleda S, Esteban JI, Viladomiu L, Martell M, Dragon E et al. Evaluation of hepatitis C virus RNA RT/PCR qualitative and quantitative second generation assays. J Virol Methods 2001;91:51-8.
65. Saldanha J, Minor P. Collaborative study to assess the suitability of an HCV RNA reference sample for detection of an HCV RNA in plasma pools by PCR. Vox Sang 1996;70:148-51.
66. Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang 1999;76:149-58.
67. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000;32: 654-9.
68. Beld M, Sentjens R, Rebers S, Weegink C, Weel J, Sol C et al. Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay. J Clin Microbiol 2002; 40:788-93.
69. Brillanti S, Garson JA, Tuke PW, Ring C, Briggs M, Masci C et al. Effect of alpha-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study. J Med Virol 1991;34:136-41.
70. Garson JA, Brillanti S, Ring C, Perini P, Miglioli M, Barbara L. Hepatitis C viraemia rebound after "successful" interferon therapy in patients with chronic non-A, non-B hepatitis. J Med Virol 1992;37:210-4.
71. Simmonds P, Zhang LQ, Watson HG, Rebus S, Ferguson ED, Balfe P et al. Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users. Lancet 1990;336:1469-72.
72. Gretch D, Corey L, Wilson J, dela Rosa C, Willson R, Carithers R Jr et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J Infect Dis 1994;169: 1219-25.
73. Podzorski RP. Molecular testing in the diagnosis and management of hepatitis C virus infection. Arch Pathol Lab Med 2002;126:285-90.
74. Compton J. Nucleic acid sequence-based amplification. Nature 1991;350:91-2.
75. Lunel F, Cresta P, Vitour D, Payan C, Dumont B, Frangeul L et al. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays. Hepatology 1999;29:528-35.
76. Chan SW, McOmish F, Holmes EC, Dow B, Peutherer JF, Follett E et al. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol 1992;73(Pt 5):1131-41.
77. Lau JY, Mizokami M, Kolberg JA, Davis GL, Prescott LE, Ohno T et al. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis 1995;171:281-9.
78. Stuyver L, Wyseur A, van Arnhem W, Lunel F, Laurent-Puig P, Pawlotsky JM et al. Hepatitis C virus genotyping by means of 5′-UR/core line probe assays and molecular analysis of untypeable samples. Virus Res 1995;38:137-57.
79. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000;13:223-35.
80. Germer JJ, Rys PN, Thorvilson JN, Persing DH. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999;37: 2625-30.
81. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
82. Smuts HE, Kannemeyer J. Genotyping of hepatitis C virus in South Africa. J Clin Microbiol 1995;33: 1679-81.
83. Constantine NT, Abdel-Hamid M, Oldach D. Rapid genotyping of hepatitis C virus. N Engl J Med 1995; 333:800.
84. Mellor J, Walsh EA, Prescott LE, Jarvis LM, Davidson F, Yap PL et al. Survey of type 6 group variants of hepatitis C virus in Southeast Asia by using a core-based genotyping assay. J Clin Microbiol 1996;34:417-23.
85. Thiers V, Jaffredo F, Tuveri R, Chodan N, Brechot C. Development of a simple restriction fragment length polymorphism (RFLP) based assay for HCV genotyping and comparative analysis with genotyping and serotyping tests. J Virol Methods 1997;65:9-17.
86. Dixit V, Quan S, Martin P, Larson D, Brezina M, DiNello R et al. Evaluation of a novel serotyping system for hepatitis C virus: strong correlation with standard genotyping methodologies. J Clin Microbiol 1995;33: 2978-83.
87. Gish RG, Qian KP, Quan S, Xu YL, Pike I, Polito A et al. Concordance between hepatitis C virus serotyping assays. J Viral Hepat 1997;4:421-2.
88. Tokita H, Okamoto H, Iizuka H, Kishimoto J, Tsuda F, Lesmana LA et al. Hepatitis C virus variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. J Gen Virol 1996;77(Pt 2):293-301.